AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL
· Real-Time Price · USD
4.65
-0.12 (-2.52%)
At close: Sep 25, 2025, 3:59 PM
4.64
-0.12%
After-hours: Sep 25, 2025, 07:27 PM EDT
AbCellera Biologics Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License Revenue | 10.45M | 167K | 651K | 218K | 370K | 180K | 185K | 186K | 226K | 372K | 165K | 154K | 147K | 231K | 86K | 190K | 263K | 20.26M |
| License Revenue Growth | +6154.49% | -74.35% | +198.62% | -41.08% | +105.56% | -2.70% | -0.54% | -17.70% | -39.25% | +125.45% | +7.14% | +4.76% | -36.36% | +168.60% | -54.74% | -27.76% | -98.70% | n/a |
| Research Fees Revenue | 6.64M | 4.07M | 10.22M | 6.29M | 5.45M | 9.77M | 8.74M | 6.41M | 9.83M | 10.57M | 11.42M | 7.51M | 12.54M | 9.33M | 4.75M | 5.13M | 5.21M | 3.99M |
| Research Fees Revenue Growth | +63.20% | -60.20% | +62.52% | +15.33% | -44.21% | +11.79% | +36.33% | -34.76% | -7.00% | -7.48% | +52.16% | -40.12% | +34.34% | +96.65% | -7.45% | -1.67% | +30.83% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 21.99M | 19.07M | 19.16M | 22.28M | 23.33M | 20.72M | 19.07M | 17.84M | 19.36M | 18.91M | 15.71M | 16.88M | 17.53M | 16.64M | 14.72M | 12.49M | 12.5M | 9M | 8.03M | 3.59M | 2.04M | 2.09M | 1.45M | 994.36K | 785.79K | 785.79K |
| Selling, General, and Administrative Revenue Growth | +15.30% | -0.50% | -13.99% | -4.48% | +12.60% | +8.61% | +6.94% | -7.88% | +2.42% | +20.37% | -6.96% | -3.71% | +5.37% | +13.05% | +17.85% | -0.08% | +38.87% | +12.13% | +123.32% | +75.75% | -2.01% | +44.37% | +45.38% | +26.54% | 0.00% | n/a |
| Research and Development Revenue | 39.21M | 42.5M | 46.08M | 40.97M | 40.93M | 39.29M | 48.62M | 37.92M | 36.47M | 52.65M | 28.25M | 26.58M | 26.68M | 26.37M | 17.21M | 17.45M | 15.05M | 12.35M | 8.64M | 7.5M | 9.14M | 4.12M | 3.31M | 2.78M | 2.01M | 2.01M |
| Research and Development Revenue Growth | -7.73% | -7.77% | +12.47% | +0.10% | +4.17% | -19.20% | +28.23% | +3.96% | -30.72% | +86.39% | +6.26% | -0.39% | +1.21% | +53.21% | -1.38% | +15.98% | +21.81% | +43.02% | +15.23% | -18.03% | +122.05% | +24.46% | +18.93% | +38.33% | 0.00% | n/a |
| Sales and Marketing Revenue | 3.01M | 2.84M | 3.14M | 3.13M | 3.14M | 3.37M | 3.1M | 3.47M | 3.84M | 3.77M | 2.69M | 3.09M | 3.12M | 2.37M | 1.83M | 1.22M | 1.29M | 2.58M | 2.23M | 626K | 547K | 437K | 470.57K | 291.42K | 250.33K | 250.33K |
| Sales and Marketing Revenue Growth | +5.88% | -9.61% | +0.29% | -0.03% | -6.81% | +8.55% | -10.61% | -9.71% | +1.86% | +40.13% | -12.88% | -0.99% | +31.65% | +29.72% | +50.12% | -6.02% | -49.77% | +15.51% | +256.54% | +14.44% | +25.17% | -7.13% | +61.47% | +16.42% | 0.00% | n/a |